Qiagen N.V.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- QIAGEN N.V. (NYSE: QGEN; Frankfurt: QIA) provides Sample to Insight solutions that enable molecular diagnostics, applied testing, academic and pharmaceutical research, and bioinformatics through products and services for extracting, analyzing and interpreting insights from DNA, RNA and proteins. The company offers sample technologies including kits, consumables and automated instruments for nucleic acid isolation and processing from blood, tissue and other materials; assay technologies such as PCR, next-generation sequencing (NGS) panels like QIAseq xHYB Long Read Panels for structural variants, HLA typing and repeat expansions, multiplex real-time PCR systems like QIAstat-Dx, and immunoassay platforms like QuantiFERON for latent TB detection; bioinformatics software and knowledge bases for data interpretation; and automation solutions including QIAmini, QIAsprint Connect and QIAsymphony Connect for high-throughput workflows. Founded in 1984 and headquartered in Venlo, Netherlands, with main operational headquarters in Hilden, Germany, and regional offices in the United States, China and Singapore, QIAGEN serves over 500,000 customers worldwide including academia, pharma/biotech R&D, clinical labs, forensics, veterinary and food safety sectors across more than 35 countries. In recent developments, QIAGEN acquired Parse Biosciences in November 2025 for $225 million upfront plus up to $55 million in milestones to enter the single-cell sequencing market supporting AI-driven biology; announced a $500 million synthetic share repurchase to complete in early January 2026 as part of over $1 billion in shareholder returns since 2024; launched QIAseq xHYB Long Read Panels in 2025 to enhance NGS target enrichment; exceeded Q3 2025 financial outlook with raised full-year adjusted EPS guidance; and advanced launches of three new sample preparation instruments in 2025-2026 targeting liquid biopsy, oncology and high-throughput applications.
Company News
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
Qiagen (NYSE:QGEN) & BioLife Solutions (NASDAQ:BLFS) Critical Contrast
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
Understanding Qiagen (QGEN) Reliance on International Revenue
Qiagen Q2 Earnings Call Highlights
Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
Qiagen (QGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
Allspring Global Investments Holdings LLC Has $100.21 Million Position in Qiagen N.V. $QGEN
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
Qiagen: New Launches Signal A Turnaround
Qiagen draws early takeover interest from EQT, Advent & KKR, Bloomberg News reports